How to Get Vyvanse in California

Who Can Prescribe Vyvanse in California

Any clinician holding a valid California license with DEA Schedule II authority can write a Vyvanse prescription. That includes physicians (MD/DO), nurse practitioners, and physician assistants. The practical differences matter if you are choosing a provider.

MDs and DOs

Physicians have unrestricted prescribing authority for Schedule II substances in California. No collaborative agreement is required. Board-certified psychiatrists and primary care physicians are the most common Vyvanse prescribers, though any licensed physician can write the script [1].

Nurse Practitioners

California's AB 890, which took effect January 1, 2023, grants NPs who meet the "103 NP" pathway full practice authority, including independent Schedule II prescribing. NPs who have not completed this pathway still prescribe under a standardized procedure with a supervising physician. Either route is valid for a Vyvanse prescription.

Physician Assistants

PAs prescribe Vyvanse under the delegation of a supervising physician. California law requires a written delegation of services agreement. In practice, most telehealth platforms and clinics satisfy this requirement internally, so the patient experience is identical.

What This Means for Patients

If your telehealth provider is a California-licensed NP or PA, verify their controlled substance furnishing number before your appointment. This avoids delays. Most established platforms handle this automatically during onboarding.

Getting Vyvanse Through Telehealth in California

California permits telehealth prescribing of Schedule II stimulants, including lisdexamfetamine. The DEA's updated telemedicine rule (finalized in 2025) allows an initial Schedule II prescription via video visit, provided the prescriber conducts an adequate medical evaluation [2].

How a Telehealth Visit Works

A standard telehealth appointment for Vyvanse involves a live video evaluation lasting 30 to 60 minutes. The prescriber reviews your medical history, screens for ADHD or binge eating disorder using validated tools (such as the ASRS-v1.1 or DSM-5 criteria), checks the California CURES prescription drug monitoring program (PDMP), and discusses risks including cardiovascular effects and substance misuse potential.

California CURES PDMP Check

California law (Health and Safety Code Section 11165.4) requires prescribers to check the CURES database before writing or renewing a Schedule II prescription. This step is non-negotiable. The CURES report shows all controlled substance fills in California over the prior 12 months, and prescribers use it to flag potential duplicate therapy or diversion risk [3].

First Visit vs. Follow-Up

Your first visit will be the longest. Expect a full psychiatric or medical history review. Follow-up visits (typically every 30 to 90 days depending on stability) are shorter, around 15 to 20 minutes, and focus on symptom response, side effects, vital signs, and refill authorization. Because Vyvanse is Schedule II, each fill requires a new prescription. Your provider cannot write "refills" on the script.

Prior Authorization for Vyvanse in California

Most insurance plans, including Medi-Cal, require prior authorization (PA) before they will cover Vyvanse at formulary pricing. PA is not a denial. It is a documentation checkpoint.

What Medi-Cal Requires

Medi-Cal covers Vyvanse for both ADHD and binge eating disorder with PA approval. The typical Medi-Cal PA for Vyvanse requires documentation of a confirmed DSM-5 diagnosis, evidence that the patient has tried and failed (or has a contraindication to) a first-line generic stimulant such as mixed amphetamine salts or methylphenidate, current CURES PDMP results, and the prescriber's clinical rationale for lisdexamfetamine specifically [4].

What Commercial Plans Require

Commercial insurers in California (Anthem Blue Cross, Blue Shield of California, Kaiser Permanente, Health Net) generally follow a step-therapy model. Step 1 is a trial of generic mixed amphetamine salts or generic methylphenidate. Step 2 is Vyvanse, authorized once step 1 has been documented as inadequate or not tolerated. Approval periods range from 6 to 12 months depending on the plan.

Timeline for PA Decisions

California law requires health plans to respond to standard PA requests within 5 business days and urgent requests within 72 hours (California Health and Safety Code Section 1367.01). In practice, many electronic PA submissions are adjudicated within 24 to 48 hours. If denied, you have the right to an expedited appeal.

How to Speed Up the Process

Submit PA requests electronically through CoverMyMeds or the plan's online portal. Include all supporting documentation (office notes, CURES report, prior trial history) with the initial submission. Incomplete submissions are the top cause of PA delays.

Labs and Screening Before Starting Vyvanse

Vyvanse does not require extensive lab work before initiation, but a baseline clinical workup reduces risk and satisfies most insurer documentation requirements.

Baseline Vitals

Blood pressure and heart rate must be measured before starting any stimulant. The American Academy of Pediatrics and the American Heart Association recommend baseline cardiovascular screening including a focused cardiac history and a resting blood pressure reading [5]. An ECG is not universally required but should be obtained if the patient has a personal or family history of structural heart disease, arrhythmia, or sudden cardiac death.

Lab Tests

A complete metabolic panel (CMP) is reasonable at baseline, particularly if the patient takes other medications metabolized hepatically. Vyvanse is converted to dextroamphetamine in red blood cells through enzymatic hydrolysis, not hepatic cytochrome P450 metabolism, so drug-drug interactions are minimal [6]. A CBC is occasionally requested. Thyroid function testing (TSH, free T4) is recommended if symptoms overlap with hypothyroidism.

Screening Tools

Validated ADHD screening instruments include the Adult ADHD Self-Report Scale (ASRS-v1.1) for adults and the Vanderbilt Assessment Scale for children. For binge eating disorder, the Binge Eating Scale (BES) is commonly used. Wigal et al. (2017) demonstrated that lisdexamfetamine produced significant improvements in ADHD symptom scores across multiple validated instruments in a controlled trial setting [7].

Filling Your Vyvanse Prescription at a California Pharmacy

Once you have a valid prescription, filling it involves a few California-specific steps worth knowing in advance.

Retail Pharmacy Access

Vyvanse is stocked at major California retail chains (CVS, Walgreens, Rite Aid, Costco) and independent pharmacies. Schedule II stimulant shortages have affected availability intermittently since 2022. If your pharmacy is out of stock, California Board of Pharmacy regulations allow the pharmacist to provide a partial fill, with the remainder dispensed within 72 hours of the original fill date [8].

503A Compounding Pharmacies

California-licensed 503A compounding pharmacies may compound lisdexamfetamine for patients with a valid prescription and a documented clinical need (such as a specific dose not commercially available or an allergy to an inactive ingredient). The California State Board of Pharmacy oversees these facilities. Compounded lisdexamfetamine is not an AB-rated generic equivalent, so insurance coverage varies.

E-Prescribing Requirements

Since 2021, California law (Business and Professions Code Section 688) requires most controlled substance prescriptions to be transmitted electronically. Paper prescriptions are permitted only in specific exemption scenarios (technological failure, emergency, or veterinary use). If your telehealth provider sends the prescription electronically to your chosen pharmacy, the script should be available for pickup within hours of the appointment.

Cost Without Insurance

Brand-name Vyvanse 30-day supply ranges from approximately $350 to $430 at California retail pharmacies without insurance. Takeda's patient assistance program (Takeda Help at Hand) may cover the full cost for eligible uninsured or underinsured patients with a household income at or below 250% of the federal poverty level [9]. GoodRx and similar discount cards can reduce cash prices to roughly $280 to $370 depending on dose and pharmacy.

Transferring a Vyvanse Prescription to California

If you are moving to California from another state, your existing Vyvanse prescription cannot simply be "transferred" the way a non-controlled medication can. Schedule II prescriptions are non-transferable under federal law (21 CFR 1306.12).

What You Need to Do

Establish care with a California-licensed prescriber. Bring your prior medical records, including the diagnosing evaluation, treatment history, and most recent office notes. A new California prescriber can issue a new prescription on your first visit if documentation supports the diagnosis and continued treatment. Request a PDMP report from your previous state to provide continuity evidence.

Interstate Telehealth

A prescriber licensed only in your previous state cannot prescribe controlled substances to be filled in California. The prescriber must hold an active California medical license. Some multi-state telehealth platforms employ providers licensed in California specifically for this reason.

Vyvanse Dosing and Monitoring in California Practice

Lisdexamfetamine is available in capsule strengths from 10 mg to 70 mg. The standard starting dose for adults with ADHD is 30 mg once daily in the morning, titrated in 10 mg or 20 mg increments at weekly intervals based on response and tolerability [6].

Titration Protocol

Most California clinicians follow the FDA-labeled titration schedule. Start at 30 mg daily. Increase by 10 to 20 mg per week. Maximum recommended dose is 70 mg daily for ADHD. For binge eating disorder, the target dose range is 50 to 70 mg daily, also initiated at 30 mg [6].

Ongoing Monitoring

Follow-up appointments should include blood pressure and heart rate measurement at every visit. Weight monitoring is recommended, particularly in pediatric patients. The prescriber should reassess treatment necessity at least annually. California CURES checks are required at each renewal. Growth velocity monitoring (height and weight percentiles) is standard in children and adolescents taking stimulants [5].

When to Consider Dose Adjustment

Dose reduction or discontinuation should be discussed if resting heart rate consistently exceeds 100 bpm, systolic blood pressure rises above 140 mmHg, the patient reports insomnia persisting beyond the first two weeks, appetite suppression leads to clinically significant weight loss (more than 5% of body weight unintentionally), or the patient develops new anxiety or agitation.

Insurance Coverage Field in California

Coverage varies significantly across California's insurance market. Here is how the major payers handle Vyvanse.

Medi-Cal

Covered with PA for ADHD and binge eating disorder. Generic lisdexamfetamine (expected to enter the market following patent litigation outcomes) may eventually shift Medi-Cal's preferred agent, but as of mid-2026, brand Vyvanse remains the covered product under PA [4].

Covered California (ACA Marketplace Plans)

Most silver and gold tier Covered California plans include Vyvanse on their formulary at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). PA and step therapy through a generic stimulant are typical. Out-of-pocket costs after PA approval range from $30 to $75 per month depending on the plan.

Kaiser Permanente California

Kaiser covers Vyvanse with PA after a documented trial of a first-line generic stimulant. Kaiser's integrated model means the PA is handled internally by the prescribing psychiatrist or primary care physician, often within 24 hours.

Employer-Sponsored Plans

Large employer plans (Anthem, Blue Shield, UnitedHealthcare, Aetna) in California generally place Vyvanse on Tier 3 with PA requirements. Copays range from $35 to $90 per fill. Some plans waive PA for patients already stabilized on Vyvanse when they enroll.

Key California Regulations Affecting Vyvanse Access

California has several state-specific rules that directly affect how patients obtain and maintain stimulant prescriptions.

Schedule II prescriptions in California expire 6 months from the date written if not filled [10]. The prescriber can write up to three sequential 30-day prescriptions on the same date ("post-dated" prescriptions), allowing a 90-day supply cycle before the next required appointment, per California Business and Professions Code Section 11159.2. Pharmacists must verify the prescriber's identity and DEA registration for every Schedule II fill. Patients under 18 require the consent of a parent or legal guardian for the initial ADHD evaluation in most clinical settings, though California's minor consent laws (Family Code Section 6924) allow minors aged 12 and older to consent to mental health treatment under certain circumstances.